Markets
BSE See NSE See 48,803.68
259.62 (0.53%)

Glenmark and Bausch Health collaborate to commercialise Ryaltris nasal spray in Canada

Shreya Chaware / Article rating: 5.0

On Monday, Glenmark pharma, a global integrated pharmaceutical company announced that it has entered into a licensing agreement with an affiliate of Bausch Health Companies Inc through its subsidiary Glenmark Specialty SA in Switzerland for the commercialisation of Glenmark’s innovative nasal spray, Ryaltris, which is under review by Health Canada.

First910111214161718Last

DSIJ MINDSHARE

12345Last

Knowledge

12345Last